Biogen and Denali Therapeutics limit the development of their experimental Parkinson’s disease drug BIIB122 after the therapy failed to meet primary and secondary endpoints in a Phase 2b clinical trial.
FDA approves Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) for adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy.
Biogen and Denali Therapeutics limit the development of their experimental Parkinson’s disease drug BIIB122 after the therapy failed to meet primary and secondary endpoints in a Phase 2b clinical trial.
FDA approves Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) for adults with unresectable or metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitor therapy.
FDA has approved Gilead Sciences’ Hepcludex (bulevirtide-gmod) for treating chronic hepatitis delta virus (HDV) infection, marking the first FDA-approved therapy for the rare but potentially life-threatening liver disease. The approval covers treatment in adults with chronic hepatitis delta virus infection who do not have cirrhosis
FDA issues an early alert about a potentially high-risk software problem involving certain heart pump controllers manufactured by Abiomed that could temporarily stop circulatory support during treatment.
